Autoimmune disease therapy firm Cabaletta Bio has raised $50m in a series B funding round. The extra capital, which follows a $38m series A, will be put to use funding the manufacture of the Pennsylvania-based company's chimeric autoantibody receptor T cell (CAAR-T) therapies. This system borrows the techniques used in chimeric antigen receptor T-cell methods for cancer treatments, and instead applies them to autoimmune diseases. The CAAR-T selectively rids mucosal pemphigus vulgaris patients of DSG3 protein-expressing B cells by using the two-1BB costimulatory domain to boost cytokine production and a CD3-zeta signalling domain to control signalling during T-cell activation.
Autoimmune disease therapy firm Cabaletta Bio has raised $50m in a series B funding round. The extra capital, which follows a $38m series A, will be put to use funding the manufacture of the Pennsylvania-based company's chimeric autoantibody receptor T cell (CAAR-T) therapies. This system borrows the techniques used in chimeric antigen receptor T-cell methods for cancer treatments, and instead applies them to autoimmune diseases. The CAAR-T selectively rids mucosal pemphigus vulgaris patients of DSG3 protein-expressing B cells by using the 4-1BB costimulatory domain to boost cytokine production and a CD3-zeta signalling domain to control signalling during T-cell activation.